Literature DB >> 31229512

Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Lan Cao1, Ahmed Basudan2, Matthew J Sikora3, Amir Bahreini3, Nilgun Tasdemir4, Kevin M Levine5, Rachel C Jankowitz6, Priscilla F McAuliffe7, David Dabbs8, Sue Haupt9, Ygal Haupt9, Peter C Lucas10, Adrian V Lee11, Steffi Oesterreich4, Jennifer M Atkinson4.   

Abstract

Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer following invasive ductal carcinoma (IDC). To identify potential genetic drivers of ILC progression, we used NanoString nCounter technology to investigate the DNA copy number (CN) in 70 well-curated primary ILC samples. We confirmed prior observations of frequent amplification of CCND1 (33%), and MYC (17%) in ILC, but additionally identified a substantial subset of ILCs with ESR1 and ERBB2 (19%) amplifications. Of interest, tumors with ESR1 CN gains (14%) and amplification (10%) were more likely to recur compared to those with normal CN. Finally, we observed that MDM4 (MDMX) was amplified in 17% of ILC samples. MDM4 knockdown in TP53 wild-type ILC cell lines caused increased apoptosis, decreased proliferation associated with cell cycle arrest, and concomitant activation of TP53 target genes. Similar effects were seen in TP53 mutant cells, indicting a TP53-independent role for MDM4 in ILC. To conclude, amplification of ESR1 and MDM4 are potential genetic drivers of ILC. These amplifications may represent actionable, targetable tumor dependencies, and thus have potential clinical implications and warrant further study.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amplification; ERBB2; ESR1; ILC; MDM4

Mesh:

Substances:

Year:  2019        PMID: 31229512      PMCID: PMC6682463          DOI: 10.1016/j.canlet.2019.06.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  46 in total

1.  MdmX represses E2F1 transactivation.

Authors:  Mark Wunderlich; Mithua Ghosh; Karen Weghorst; Steven J Berberich
Journal:  Cell Cycle       Date:  2004-04-01       Impact factor: 4.534

2.  MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.

Authors:  Yetao Jin; Shelya X Zeng; Xiao-Xin Sun; Hunjoo Lee; Christine Blattner; Zhixiong Xiao; Hua Lu
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

3.  Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.

Authors:  R X Song; G Mor; F Naftolin; R A McPherson; J Song; Z Zhang; W Yue; J Wang; R J Santen
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

4.  High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer.

Authors:  Daniel E Stange; Bernhard Radlwimmer; Falk Schubert; Frank Traub; Andreas Pich; Grischa Toedt; Frank Mendrzyk; Ulrich Lehmann; Roland Eils; Hans Kreipe; Peter Lichter
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

Authors:  Fabrice Andre; Bastien Job; Philippe Dessen; Attila Tordai; Stefan Michiels; Cornelia Liedtke; Catherine Richon; Kai Yan; Bailang Wang; Gilles Vassal; Suzette Delaloge; Gabriel N Hortobagyi; W Fraser Symmans; Vladimir Lazar; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.

Authors:  Davide Danovi; Erik Meulmeester; Diego Pasini; Domenico Migliorini; Maria Capra; Ruth Frenk; Petra de Graaf; Sarah Francoz; Patrizia Gasparini; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Aart G Jochemsen; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

8.  Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas.

Authors:  P T Simpson; J S Reis-Filho; M B K Lambros; C Jones; D Steele; A Mackay; M Iravani; K Fenwick; T Dexter; A Jones; L Reid; L Da Silva; S J Shin; D Hardisson; A Ashworth; F C Schmitt; J Palacios; S R Lakhani
Journal:  J Pathol       Date:  2008-07       Impact factor: 7.996

9.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

10.  Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

Authors:  Katja Lundgren; Karolina Holm; Bo Nordenskjöld; Ake Borg; Göran Landberg
Journal:  Breast Cancer Res       Date:  2008-09-29       Impact factor: 6.466

View more
  8 in total

Review 1.  Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.

Authors:  Nikhil Pramod; Akanksha Nigam; Mustafa Basree; Resham Mawalkar; Saba Mehra; Neelam Shinde; Gary Tozbikian; Nicole Williams; Sarmila Majumder; Bhuvaneswari Ramaswamy
Journal:  Oncologist       Date:  2021-03-16

Review 2.  Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Authors:  Jason A Mouabbi; Amy Hassan; Bora Lim; Gabriel N Hortobagyi; Debasish Tripathy; Rachel M Layman
Journal:  Breast Cancer Res Treat       Date:  2022-03-26       Impact factor: 4.872

Review 3.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

4.  ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.

Authors:  Zheqi Li; Olivia McGinn; Yang Wu; Amir Bahreini; Nolan M Priedigkeit; Kai Ding; Sayali Onkar; Caleb Lampenfeld; Carol A Sartorius; Lori Miller; Margaret Rosenzweig; Ofir Cohen; Nikhil Wagle; Jennifer K Richer; William J Muller; Laki Buluwela; Simak Ali; Tullia C Bruno; Dario A A Vignali; Yusi Fang; Li Zhu; George C Tseng; Jason Gertz; Jennifer M Atkinson; Adrian V Lee; Steffi Oesterreich
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

Review 5.  Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.

Authors:  Amy E McCart Reed; Lauren Kalinowski; Peter T Simpson; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2021-01-07       Impact factor: 6.466

Review 6.  Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

Authors:  George Sflomos; Koen Schipper; Thijs Koorman; Amanda Fitzpatrick; Steffi Oesterreich; Adrian V Lee; Jos Jonkers; Valerie G Brunton; Matthias Christgen; Clare Isacke; Patrick W B Derksen; Cathrin Brisken
Journal:  Cancers (Basel)       Date:  2021-10-27       Impact factor: 6.639

7.  Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis.

Authors:  Sarah A Jeffreys; Therese M Becker; Sarah Khan; Patsy Soon; Hans Neubauer; Paul de Souza; Branka Powter
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

8.  Identification of the specific microRNAs and competitive endogenous RNA mechanisms in osteoporosis.

Authors:  Junyi Hong; Fusheng Ye; Binjia Yu; Junwei Gao; Feicheng Qi; Wei Wang
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.